Your browser doesn't support javascript.
Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization.
Shan, Sisi; Luo, Shitong; Yang, Ziqing; Hong, Junxian; Su, Yufeng; Ding, Fan; Fu, Lili; Li, Chenyu; Chen, Peng; Ma, Jianzhu; Shi, Xuanling; Zhang, Qi; Berger, Bonnie; Zhang, Linqi; Peng, Jian.
  • Shan S; NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China.
  • Luo S; HeliXon Limited, Beijing 100084, China.
  • Yang Z; NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China.
  • Hong J; NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China.
  • Su Y; Department of Computer Science, University of Illinois at Urbana-Champaign, Champaign, IL 61822.
  • Ding F; HeliXon Limited, Beijing 100084, China.
  • Fu L; NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China.
  • Li C; NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China.
  • Chen P; NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China.
  • Ma J; HeliXon Limited, Beijing 100084, China.
  • Shi X; NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China.
  • Zhang Q; NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China.
  • Berger B; Computer Science & Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Zhang L; Department of Mathematics, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Peng J; NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China.
Proc Natl Acad Sci U S A ; 119(11): e2122954119, 2022 03 15.
Article in English | MEDLINE | ID: covidwho-1721790
ABSTRACT
SignificanceSARS-CoV-2 continues to evolve through emerging variants, more frequently observed with higher transmissibility. Despite the wide application of vaccines and antibodies, the selection pressure on the Spike protein may lead to further evolution of variants that include mutations that can evade immune response. To catch up with the virus's evolution, we introduced a deep learning approach to redesign the complementarity-determining regions (CDRs) to target multiple virus variants and obtained an antibody that broadly neutralizes SARS-CoV-2 variants.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Broadly Neutralizing Antibodies / SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Proc Natl Acad Sci U S A Year: 2022 Document Type: Article Affiliation country: Pnas.2122954119

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Broadly Neutralizing Antibodies / SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Proc Natl Acad Sci U S A Year: 2022 Document Type: Article Affiliation country: Pnas.2122954119